Bellevue Group AG Boosts Stake in Oxford Immunotec Global PLC (OXFD)

Bellevue Group AG raised its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 38.2% in the fourth quarter, Holdings Channel reports. The fund owned 306,606 shares of the company’s stock after purchasing an additional 84,769 shares during the quarter. Bellevue Group AG’s holdings in Oxford Immunotec Global were worth $3,918,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of OXFD. Engineers Gate Manager LP bought a new position in shares of Oxford Immunotec Global in the third quarter worth about $188,000. Renaissance Technologies LLC lifted its holdings in shares of Oxford Immunotec Global by 84.7% in the second quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after acquiring an additional 9,658 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Oxford Immunotec Global in the third quarter worth about $279,000. Rhumbline Advisers lifted its holdings in shares of Oxford Immunotec Global by 50.7% in the fourth quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock worth $419,000 after acquiring an additional 11,022 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Oxford Immunotec Global in the third quarter worth about $445,000. 91.12% of the stock is owned by hedge funds and other institutional investors.

Get Oxford Immunotec Global alerts:

In other news, CEO Peter Wrighton-Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $16.99, for a total value of $169,900.00. Following the completion of the transaction, the chief executive officer now owns 413,469 shares of the company’s stock, valued at $7,024,838.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $14.25, for a total value of $42,750.00. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $85,500. The disclosure for this sale can be found here. Insiders sold 23,000 shares of company stock valued at $361,750 in the last ninety days. 6.61% of the stock is currently owned by insiders.

OXFD stock opened at $16.70 on Wednesday. Oxford Immunotec Global PLC has a 12 month low of $10.94 and a 12 month high of $19.19. The stock has a market capitalization of $435.73 million, a PE ratio of -12.28 and a beta of 0.33.

A number of research firms have recently commented on OXFD. Piper Jaffray Companies reissued an “overweight” rating on shares of Oxford Immunotec Global in a report on Sunday, November 11th. BidaskClub cut shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Wednesday, December 5th. ValuEngine cut shares of Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 1st. Finally, Zacks Investment Research raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Thursday, January 10th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Oxford Immunotec Global currently has a consensus rating of “Buy” and a consensus price target of $17.50.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4200502/bellevue-group-ag-boosts-stake-in-oxford-immunotec-global-plc-oxfd.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Further Reading: What is a Lock-Up Period?

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).